Navigation Links
Enbrelr Enters Safer Zone After Recent Research

Latest studies have declared ENBRELR (etanercept) safe to be used to treat psoriasis up to an extended period of two and half years//. The result of the current studies were presented at the 15th European Academy of Dermatology and Venereology (EADV)Congress . ENBREL is a 'Biologic Medicine which means it is synthesized using recombinant DNA or rDNA derived protein using current principles of biotechnology.

This biologic medicine acts by inhibiting one of the main mediators which triggers off inflammatory processes. Enbrel happens to be topmost biologic therapeutic clinically approved worldwide, It is also less cumbersome for patients as it is marketed in convenient 25mg and 50mg syringes making it most adaptable for treatment purposes.

Bruce Strober MD PhD, co director of the Psoriasis and Psoriatic Arthritis Center at New York University mentions that that these findings are very significant as it confirms the parameters within which Enbrel is safe to be used, and also provides valuable information regarding the use of other biologic medicines as well in the long run.

About 5.1 million people is affected by Psoriasis in U.K alone, according to statistics. The most common type of Psoriasis presents itself in the form of plaques over affected skin surface characterized by thickening of skin which looks reddish with superfluous flaky white scales which fall away on being scratched. Most common symptoms associated with these lesions are severe intolerable itching and redness of skin apart from the drying and scaling away of skin. It is probable that an abnormal response from the immune system of the body cause the skin cells to grow and multiply excessively.

In the 48 week Open Label study that was conducted it was clear that ENBREL produced no unpalatable side effects with extended dosages upto2.5 years when compared with randomized Placebo controlled Parent Studies. No further safety signals were iden tified. These findings support the conclusions derived from previous research done giving ENBREL50mg twice a week in a 96-week study.
MON
'"/>




Related medicine news :

1. More Doctors Suspended As Strike Enters Seventh Day
2. Doctors Strike In Andhra Enters The Second Day
3. Anti-Quota Stir: Stalemate Continues; Fast Enters 10th Day
4. AIIMS Strike Enters Second day, Support Continues To Pour In
5. JIPMER Strike Enters Eighth Day
6. The Food Pyramid Guide Enters Supermarkets
7. Vandetanib Study Enters Third Phase
8. Crucells Rabies MAb Enters Phase I Trial in India
9. Heart Surgery Is Getting Safer for the Old
10. Estrogen Patch is Safer than Pills for Heart
11. Traffic Violations Result in Safer Drivers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... September 22, 2017 , ... First Choice ... celebrating the one year anniversary of its Houston-Fallbrook facility. , “We are ... Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has been a ...
(Date:9/22/2017)... ... ... “Letters From Home”: a moving compilation of letters that remind readers of the ... is the creation of published author, John Allred, a passionate leader of ministry to ... who has traveled and ministered on four continents. , “It is my hope and ...
(Date:9/21/2017)... , ... September 21, 2017 , ... With ProSlideshow Portrait ... and easy to do. Users can select from up to two layers of subject ... click of a mouse all within Final Cut Pro X. , With ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... learn with Infinity Behavioral Health Services for professionals in the addiction treatment industry ... Payer Audit . , Insurance companies and state and federal governments are ...
(Date:9/21/2017)... ... September 21, 2017 , ... Bill Howe Plumbing’s mission is to create an ... to the community. For over 37 years, they have operated with their mission at ... in San Diego. They were chosen as the Best San Diego plumber in ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: